LIGAND PHARMACEUTICALS INCORPORATED Income (Loss) from Continuing Operations before Income Taxes, Domestic
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $126.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $126.43M.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$25.86M, a 141.61% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $62.14M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $126.43M 10-K · filed 2026-02-27 |
| 2024-12-31 | -$25.86M 10-K · filed 2026-02-27 |
| 2023-12-31 | $62.14M 10-K · filed 2026-02-27 |